EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.05
+1.19 (+5.21%)
At close: 4:00PM EST

24.10 +0.05 (0.21%)
After hours: 7:58PM EST

Stock chart is not supported by your current browser
Previous Close22.86
Open23.22
Bid24.00 x 4000
Ask24.02 x 1000
Day's Range22.71 - 24.19
52 Week Range13.42 - 31.79
Volume5,983,201
Avg. Volume4,296,226
Market Cap7.191B
Beta (3Y Monthly)2.43
PE Ratio (TTM)20.50
EPS (TTM)1.17
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Trade prices are not sourced from all markets
  • Here’s your guide to the upcoming biotechnology takeover wave
    MarketWatch6 hours ago

    Here’s your guide to the upcoming biotechnology takeover wave

    Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.

  • How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval
    American City Business Journals13 hours ago

    How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval

    Even in the days after Bristol-Myers Squibb Co. threw an experimental cancer drug back to Exelixis Inc. nearly a decade ago, there were signs of hope: strong signals from a broad trial that tested the drug across nine tumor types. One of those signals was confirmed Monday as the Food and Drug Administration approved that drug — branded as Cabometyx — as one of a handful of options for people with the most common kind of liver cancer. It is the fourth FDA approval of "cabo" for Alameda-based Exelixis (NASDAQ: EXEL), which eight years ago looked on the ropes when Bristol-Myers Squibb (NYSE: BMY) cut loose from a long-term partnership.

  • Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
    Zacks14 hours ago

    Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

    Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

  • Markit15 hours ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    # Exelixis Inc ### NASDAQ/NGS:EXEL View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for EXEL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $5.21 billion over the last one-month into ETFs that hold EXEL are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRE15 hours ago

    Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine

    NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...

  • 5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
    Zacksyesterday

    5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

    Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

  • MarketWatchyesterday

    Exelixis stock up more than 4% after FDA drug approval

    Shares of Exelixis Inc. rose more than 4% in the extended session Monday after the Alameda, Calif., biotech company said the U.S. Food and Drug Administration has approved its Cabometix drug for patients with certain types of advanced liver cancer who have previously been treated with another drug. Exelixis stock ended the regular trading day down 3.8%.

  • Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
    Business Wireyesterday

    Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

    – Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –

  • Benzinga2 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...

  • Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
    Zacks4 days ago

    Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Exelixis (EXEL) closed at $23.76, marking a -1.29% move from the previous day.

  • How Many Insiders Sold Exelixis, Inc. (NASDAQ:EXEL) Shares?
    Simply Wall St.4 days ago

    How Many Insiders Sold Exelixis, Inc. (NASDAQ:EXEL) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • 3 Biotech Stocks Bubbling Away
    Investopedia5 days ago

    3 Biotech Stocks Bubbling Away

    Merger and acquisition activity in the healthcare sector has biotech stocks soaring. Explore three stocks feeling the tailwind.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    # Exelixis Inc ### NASDAQ/NGS:EXEL View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for EXEL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding EXEL is favorable, with net inflows of $8.82 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • One Pharma's Approval Just Helped This Highly Rated Biotech Stock
    Investor's Business Daily7 days ago

    One Pharma's Approval Just Helped This Highly Rated Biotech Stock

    Exelixis will receive a $20 million payout after Japanese partner Daiichi Sankyo gained approval for a hypertension treatment — prodding Exelixis stock to hit an eight-month high Tuesday.

  • Is Exelixis (EXEL) Outperforming Other Medical Stocks This Year?
    Zacks8 days ago

    Is Exelixis (EXEL) Outperforming Other Medical Stocks This Year?

    Is (EXEL) Outperforming Other Medical Stocks This Year?

  • Business Wire8 days ago

    Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan

    Exelixis, Inc. (EXEL) today announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO™ 1.25 mg, 2.5 mg, and 5 mg, as a treatment for patients with hypertension. This approval allows for the marketing of MINNEBRO for this indication within Japan. MINNEBRO is a compound identified during the prior research collaboration between Exelixis and Daiichi Sankyo, which the companies entered into in March 2006, and has been subsequently developed by Daiichi Sankyo.

  • Sarepta Therapeutics Stock Rose 96% in 2018
    Market Realist8 days ago

    Sarepta Therapeutics Stock Rose 96% in 2018

    Who Is Eyeing Sarepta Therapeutics Now? ## Stock performance On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its close of $106.67 on January 3. Sarepta Therapeutics stock grew from $55.64 at the close of market on December 29, 2017, to reach $109.13 at the close of market on December 31, 2018, which represents ~96% growth over 2018. On January 2, 2019, Sarepta Therapeutics stock closed at $107.50, which is ~35% below its 52-week high of $176.50 on June 19, 2018. The company hit its 52-week low of $26.26 on February 13, 2018. ## Recent developments In December 2018, Sarepta Therapeutics (SRPT) completed the submission of its continuing NDA (new drug application) that seeks approval of its golodirsen for the treatment of individuals with Duchenne muscular dystrophy with genetic mutations associated to skipping exon 53 Duchenne gene. Sarepta Therapeutics’ golodirsen is an engineered phosphorodiamidate morpholino oligomer for the treatment of DMD with genetic mutations of skipping exon 53 of the DMD gene. ## Analyst recommendations Of the 24 analysts tracking Sarepta Therapeutics in January 2019, nine of them recommended a “strong buy,” while 14 analysts recommended a “buy” rating. One analyst recommended a “hold” for Sarepta Therapeutics in January. On January 7, Sarepta Therapeutics had a consensus 12-month target price of $194.36, which represents a ~68.38% return on investment over the next 12-months. ## Peers’ ratings In January 2018, of 27 analysts tracking BioMarin Pharmaceuticals (BMRN), ~78% of them recommended “buys.” Of the 11 analysts tracking Exelixis (EXEL), ~73% of them recommended “buys.” Of the 11 analysts tracking Nektar Therapeutics (NKTR), ~82% of them recommended “buys.” On January 7, BioMarin Pharmaceuticals (BMRN), Exelixis (EXEL), and Nektar Therapeutics (NKTR) had a consensus 12-month target price of $120.3, $28.78, and $78.89, respectively, which represents ~38.12%, ~38.83%, and a ~132.30% return on investment over the next 12 months. Continue to Next Part Browse this series on Market Realist: * Part 2 - How Is Sarepta Therapeutics Positioned in January? * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Top 10 Stocks Under $20
    Zacks11 days ago

    Top 10 Stocks Under $20

    Today we've highlighted ten stocks that are currently trading for under $20 per share. These stocks currently have seen positive earnings estimate revisions, and a variety of other factors make these companies stand out as having strong upside potential.

  • ACCESSWIRE16 days ago

    Biotech Companies in the News

    HENDERSON, NV / ACCESSWIRE / December 31, 2018 / Several biotech companies have released major announcements this holiday season setting themselves up for a strong start to 2019. We are highlighting: Endonovo ...

  • Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
    Zacks19 days ago

    Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

    Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

  • Spectrum Pharmaceuticals: Analysts’ Recommendations in December
    Market Realist19 days ago

    Spectrum Pharmaceuticals: Analysts’ Recommendations in December

    On December 21, Spectrum Pharmaceuticals’ stock price closed at $7.24, which was ~13.30% growth from the close of $6.39 on December 20. On December 20, Spectrum Pharmaceuticals’ stock price declined ~38.79% to $6.39 from the close of $10.44 on December 19. The company hit its 52-week low of $6.22 on December 20.

  • 5 Excellent GARP Picks With Cheap PEG Ratio
    Zackslast month

    5 Excellent GARP Picks With Cheap PEG Ratio

    Although PEG ratio is categorized under value investing, this strategy follows the principles of both growth and value investing.

  • 3 Biotechs Gilead Sciences Could Buy in March
    Motley Foollast month

    3 Biotechs Gilead Sciences Could Buy in March

    With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.

  • Zackslast month

    5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

    There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.